A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From a Prograf Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf Based Immunosuppressive Regimen, Including a Long-Term Follow-Up
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Tacrolimus (Primary)
- Indications Allotransplant rejection
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 30 Jun 2017 Planned End Date changed from 1 Jun 2026 to 1 May 2026.
- 01 Feb 2017 This trial has been completed in France (end date: 2016-10-28) as per European Clinical Trials Database.
- 30 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2026.